Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mL recall — Central Admixture Pharmacy Services Inc (Class III)
Central Admixture Pharmacy Services Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mL — a Class III recall, initiated 2026-07-16 and posted to the FDA enforcement report on 2026-08-12, under recall number D-0740-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Incorrect Product Formulation”. From the product description, the form is injection, the strength given is 416.8 mL and it is marked Rx only. Distribution is recorded as “GA only” — Limited / regional distribution, with the recalling firm on record in GA, United States. It is the only recall number the FDA has filed under event ID 99535. Central Admixture Pharmacy Services Inc accounts for 2 recall records in the indexed dataset. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0740-2026 |
|---|---|
| FDA event ID | 99535 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Central Admixture Pharmacy Services Inc |
| Recall initiated | 2026-07-16 |
| Reported by FDA | 2026-08-12 |
| Report lag | 27 days from initiation to report |
| Distribution | GA only — Limited / regional distribution |
| Firm location on record | GA, United States |
| Product description (source) | Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient specific), Compound Volume 416.8 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admixture Pharmacy Services, Inc., Atlanta, 1750 Corp Dr. Ste 725, Norcross, GA 30093 (844) 903-6418 |
Reason reported by FDA
Incorrect Product Formulation
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
3 identifying values matched by exact pattern in the 40-word product description above; each is a literal substring of it.
| Product named | Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag |
|---|---|
| Form | Injection |
| Strength | 416.8 mL |
| Marketing category | Rx only |
Other indexed recalls from Central Admixture Pharmacy Services Inc
2 indexed records name Central Admixture Pharmacy Services Inc as the recalling firm, across 2 FDA events, reported 2026-07-01 to 2026-08-12. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 1295 mL | D-0618-2026 | Class II | 1295 mL · Injection | 2026-07-01 |
Reported in the same month (2026-08)
11 enforcement reports carry a report date in 2026-08; these 3 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Dabigatran Etexilate Capsules, 150 mg | D-0737-2026 | Ascend Laboratories, LLC | Class III | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0738-2026 | Ascend Laboratories, LLC | Class III | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0739-2026 | Ascend Laboratories, LLC | Class III | 2026-08-05 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 10 nearest to 2026-08-12 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Lidolog Kit, 2% | D-0713-2026 | Asclemed Usa Inc. | 2% · Injection | 2026-07-29 |
| Dabigatran etexilate Capsules, 110 mg | D-0735-2026 | Ascend Laboratories, LLC | 110 mg · Capsules | 2026-07-29 |
| Dabigatran etexilate Capsules, 150 mg | D-0736-2026 | Ascend Laboratories, LLC | 150 mg · Capsules | 2026-07-29 |
| Fexofenadine Hydrochloride Tablets, 180 mg | D-0654-2026 | Sun Pharmaceutical Industries Inc | 180 mg · Tablets | 2026-07-08 |
| hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL | D-0619-2026 | Ani Pharmaceuticals, Inc. | 10 mg/5 mL · Oral Solution | 2026-07-01 |
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Nicotine Transdermal System Patch, 14 mg | D-0550-2026 | Aveva Drug Delivery Systems, Inc. | 14 mg · Transdermal System | 2026-06-03 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Central Admixture Pharmacy Services Inc (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0740-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0740-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-08-12
- Ingested
- 2026-08-22
- Record hash
7351d6986f0c2a58
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.